Lakewood-Amedex Biotherapeutics Inc. (LABT): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of LABT were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No LABT insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LABT short interest
Moderate short interest. 6.5% of LABT shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 3%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 152,917 LABT shares were sold short, 6.5% of the shares outstanding, up 69.8% from the report before. At the average daily volume of 6.76M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 152,917 | 6.45% | +70% | 6.76M | 1.0 |
| Oct 15, 2026 | 90,040 | 3.80% | -31% | 874,150 | 1.0 |
| Sep 30, 2026 | 130,722 | 5.52% | +147% | 3.34M | 1.0 |
| Sep 15, 2026 | 52,967 | 2.24% | -14% | 1.00M | 1.0 |
| Aug 31, 2026 | 61,402 | 2.59% | +9% | 1.36M | 1.0 |
| Aug 14, 2026 | 56,253 | 2.37% | -55% | 140,397 | 1.0 |
| Jul 31, 2026 | 126,080 | 1.80% | +425% | 6.66M | 1.0 |
| Jul 15, 2026 | 24,029 | 0.34% | -36% | 379,127 | 1.0 |
| Jun 30, 2026 | 37,772 | 0.54% | -48% | 299,767 | 1.0 |
| Jun 15, 2026 | 73,164 | 1.05% | +88% | 362,400 | 1.0 |
| May 29, 2026 | 39,018 | 0.56% | -74% | 4.36M | 1.0 |
| May 15, 2026 | 148,551 | 2.12% | +96% | 4.36M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Lakewood-Amedex Biotherapeutics company events
Lakewood-Amedex Biotherapeutics filed 5 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026AgreementLakewood-Amedex Biotherapeutics Inc. entered into a Share Redemption Agreement, dated as of November 2, 2026 with Shakawe Capital LLC, the holder of all of the outstanding shares of the Company’s Series C Convertible Preferred Stock, par value $0.0001 per share. Filing
- Sep 29, 2026VoteReported shareholder vote results. Filing
- Jul 15, 2026AnnouncementShared information with investors. Filing
- Jun 17, 2026SharesChanged the rights of its shareholders. Filing
- Apr 28, 2026LeadershipThe Board of Directors of Lakewood-Amedex Biotherapeutics Inc. appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Lakewood-Amedex Biotherapeutics financials
Famous investors that hold LABT
1 of the 50 well-known investors we track reported holding LABT in their latest 13F filing. The largest position is Ken Griffin's, worth $18.2K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 19,008 | $18.2K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Lakewood-Amedex Biotherapeutics Inc. (LABT) stock
Are LABT insiders buying or selling?
No LABT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in LABT?
As of Oct 30, 2026, 152,917 LABT shares were sold short, 6.5% of the shares outstanding, up 69.8% from the report before. At the average daily volume of 6.76M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold LABT?
1 of the 50 well-known investors we track reported LABT in their latest 13F filing, including Ken Griffin. The largest position is worth $18.2K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.